{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:26:08Z","timestamp":1792178768086,"version":"4.4.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001170","name":"Cancer Council Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001801","name":"University of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001063","name":"Raine Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006065","name":"Department of Health, Government of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001106","name":"New South Wales Workers' Compensation Dust Disease Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001106","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016233","name":"Simon Lee Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016233","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA\u20104) and the programmed cell death protein 1\/ligand 1 (PD-1\/PD-L1) are now a treatment option for multiple cancer types. However, as a monotherapy, objective responses only occur in a minority of patients. Chemotherapy is widely used in combination with immune checkpoint blockade (ICB). Although a variety of isolated immunostimulatory effects have been reported for several classes of chemotherapeutics, it is unclear which chemotherapeutics provide the most benefit when combined with ICB. We investigated 10 chemotherapies from the main canonical classes dosed at the clinically relevant maximum tolerated dose in combination with anti\u2010CTLA-4\/anti-PD-L1 ICB. We screened these chemo-immunotherapy combinations in two murine mesothelioma models from two different genetic backgrounds, and identified chemotherapies that produced additive, neutral or antagonistic effects when combined with ICB. Using flow cytometry and bulk RNAseq, we characterized the tumor immune milieu in additive chemo-immunotherapy combinations. 5-fluorouracil (5-FU) or cisplatin were additive when combined with ICB while vinorelbine and etoposide provided no additional benefit when combined with ICB. The combination of 5-FU with ICB augmented an inflammatory tumor microenvironment with markedly increased CD8<jats:sup>+<\/jats:sup> T cell activation and upregulation of IFN\u03b3, TNF\u03b1 and IL-1\u03b2 signaling. The effective anti\u2010tumor immune response of 5-FU chemo-immunotherapy was dependent on CD8<jats:sup>+<\/jats:sup> T cells but was unaffected when TNF\u03b1 or IL-1\u03b2 cytokine signaling pathways were blocked. Our study identified additive and non-additive chemotherapy\/ICB combinations and suggests a possible role for increased inflammation in the tumor microenvironment as a basis for effective combination therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2022.872295","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T14:06:17Z","timestamp":1652277977000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations"],"prefix":"10.3389","volume":"13","author":[{"given":"Nicola","family":"Principe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne J.","family":"Aston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danika E.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin M.","family":"Tilsed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Loong","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem Joost","family":"Lesterhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab Plus Ipilimumab in Advanced Non\u2013Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation With Chemotherapy in the Era of Immune Checkpoint Inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/eji.201444722","article-title":"Tumor-Infiltrating Dendritic Cells Exhibit Defective Cross-Presentation of Tumor Antigens, But Is Reversed by Chemotherapy","volume":"45","author":"McDonnell","year":"2015","journal-title":"Eur J Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.10.4905","article-title":"Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather Than Cross-Tolerizing Host Tumor-Specific CD8 T Cells","volume":"170","author":"Nowak","year":"2003","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25756","article-title":"Gemcitabine Depletes Regulatory T-Cells in Human and Mice and Enhances Triggering of Vaccine-Specific Cytotoxic T-Cells","volume":"129","author":"Rettig","year":"2011","journal-title":"Int J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.04.001","article-title":"Neoadjuvant Chemo-Immunotherapy Modifies CD4(+)CD25(+) Regulatory T Cells (Treg) in Non-Small Cell Lung Cancer (NSCLC) Patients","volume":"85","author":"Pircher","year":"2014","journal-title":"Lung Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.06.016","article-title":"Cisplatin and Oxaliplatin Induce Similar Immunogenic Changes in Preclinical Models of Head and Neck Cancer","volume":"95","author":"Park","year":"2019","journal-title":"Oral Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43656","article-title":"Platinum-Based Drugs Disrupt STAT6-Mediated Suppression of Immune Responses Against Cancer in Humans and Mice","volume":"121","author":"Lesterhuis","year":"2011","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20833","article-title":"Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials","volume":"3","author":"Schmidt","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-Line Nivolumab Plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab Plus Platinum\u2013Etoposide Versus Platinum\u2013Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab With First-Line Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma (DREAM): A Multicentre, Single-Arm, Phase 2 Trial With a Safety Run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910520609","article-title":"Establishment of a Murine Model of Malignant Mesothelioma","volume":"52","author":"Davis","year":"1992","journal-title":"Int J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.10.5051","article-title":"IL-2 Intratumoral Immunotherapy Enhances CD8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2","volume":"171","author":"Jackaman","year":"2003","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3677-7","article-title":"A Systematic Investigation of the Maximum Tolerated Dose of Cytotoxic Chemotherapy With and Without Supportive Care in Mice","volume":"17","author":"Aston","year":"2017","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7816","article-title":"Sensitization to Immune Checkpoint Blockade Through Activation of a STAT1\/NK Axis in the Tumor Microenvironment","volume":"11","author":"Zemek","year":"2019","journal-title":"Sci Transl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3519","article-title":"Near-Optimal Probabilistic RNA-Seq Quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.12688\/f1000research.7563.1","article-title":"Differential Analyses for RNA-Seq: Transcript-Level Estimates Improve Gene-Level Inferences","volume":"4","author":"Soneson","year":"2015","journal-title":"F1000Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated Estimation of Fold Change and Dispersion for RNA-Seq Data With Deseq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.90","article-title":"Gene Set Knowledge Discovery With Enrichr","volume":"1","author":"Xie","year":"2021","journal-title":"Curr Protoc"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal Analysis Approaches in Ingenuity Pathway Analysis","volume":"30","author":"Kramer","year":"2014","journal-title":"Bioinformatics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btm369","article-title":"GSEA-P: A Desktop Application for Gene Set Enrichment Analysis","volume":"23","author":"Subramanian","year":"2007","journal-title":"Bioinformatics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.645","article-title":"The Effect of Joint Exposures: Examining the Presence of Interaction","volume":"75","author":"de Mutsert","year":"2009","journal-title":"Kidney Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.12.003","article-title":"Chemotherapy and Immunotherapy: Mapping the Road Ahead","volume":"39","author":"Cook","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1451-5","article-title":"Synergy Between Chemotherapeutic Agents and CTLA-4 Blockade in Preclinical Tumor Models","volume":"62","author":"Jure-Kunkel","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0076-z","article-title":"Vinorelbine, Cyclophosphamide and 5-FU Effects on the Circulating and Intratumoural Landscape of Immune Cells Improve Anti-PD-L1 Efficacy in Preclinical Models of Breast Cancer and Lymphoma","volume":"118","author":"Orecchioni","year":"2018","journal-title":"Br J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13337","article-title":"Contrasting Effects of Cyclophosphamide on Anti-CTL-Associated Protein 4 Blockade Therapy in Two Mouse Tumor Models","volume":"108","author":"Iida","year":"2017","journal-title":"Cancer Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine Selectively Eliminates Splenic Gr-1+\/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.429","article-title":"Impact of CTLA-4 Blockade in Conjunction With Metronomic Chemotherapy on Preclinical Breast Cancer Growth","volume":"116","author":"Parra","year":"2017","journal-title":"Br J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061895","article-title":"Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity","volume":"8","author":"Lesterhuis","year":"2013","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1494111","article-title":"Combination Immune Checkpoint Blockade as an Effective Therapy for Mesothelioma","volume":"7","author":"Fear","year":"2018","journal-title":"Oncoimmunology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2217\/lmt.14.27","article-title":"Mouse Models of Mesothelioma: Strengths, Limitations and Clinical Translation","volume":"3","author":"Robinson","year":"2014","journal-title":"Lung Cancer Management"},{"key":"B35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12865-016-0167-7","article-title":"Repeated Cycles of 5-Fluorouracil Chemotherapy Impaired Anti-Tumor Functions of Cytotoxic T Cells in a CT26 Tumor-Bearing Mouse Model","volume":"17","author":"Wu","year":"2016","journal-title":"BMC Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021329","article-title":"Chemotherapy Efficacy After First-Line Immunotherapy in 18 Advanced Melanoma Patients","volume":"99","author":"Saint-Jean","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"101056","DOI":"10.1016\/j.isci.2020.101056","article-title":"Chemotherapy But Not the Tumor Draining Lymph Nodes Determine the Immunotherapy Response in Secondary Tumors","volume":"23","author":"Zhao","year":"2020","journal-title":"iScience"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1838","article-title":"Therapeutic Synergy of Human Papillomavirus E7 Subunit Vaccines Plus Cisplatin in an Animal Tumor Model: Causal Involvement of Increased Sensitivity of Cisplatin-Treated Tumors to CTL-Mediated Killing in Therapeutic Synergy","volume":"13","author":"Bae","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI40269","article-title":"Chemotherapy Enhances Tumor Cell Susceptibility to CTL-Mediated Killing During Cancer Immunotherapy in Mice","volume":"120","author":"Ramakrishnan","year":"2010","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.902426","article-title":"Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models","volume":"23","author":"Cui","year":"2017","journal-title":"Med Sci Monit"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000807","article-title":"Upfront Dose-Reduced Chemotherapy Synergizes With Immunotherapy to Optimize Chemoimmunotherapy in Squamous Cell Lung Carcinoma","volume":"8","author":"He","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084927","article-title":"Combinatorial PD-1 Blockade and CD137 Activation has Therapeutic Efficacy in Murine Cancer Models and Synergizes With Cisplatin","volume":"8","author":"Wei","year":"2013","journal-title":"PloS One"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100587","article-title":"HIF-1alpha Regulates Function and Differentiation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment","volume":"207","author":"Corzo","year":"2010","journal-title":"J Exp Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25004","article-title":"Targeting Tie-2\/Angiopoietin Axis in Experimental Mesothelioma Confers Differential Responses and Raises Predictive Implications","volume":"9","author":"Magkouta","year":"2018","journal-title":"Oncotarget"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3523","article-title":"Metformin in Combination With 5-Fluorouracil Suppresses Tumor Growth by Inhibiting the Warburg Effect in Human Oral Squamous Cell Carcinoma","volume":"49","author":"Harada","year":"2016","journal-title":"Int J Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01846-x","article-title":"Targeting HIF-1 Alpha Transcriptional Activity Drives Cytotoxic Immune Effector Cells Into Melanoma and Improves Combination Immunotherapy","volume":"40","author":"Lequeux","year":"2021","journal-title":"Oncogene"},{"key":"B47","doi-asserted-by":"publisher","first-page":"115235","DOI":"10.1016\/j.bmc.2019.115235","article-title":"Small Molecules Targeting HIF-1alpha Pathway for Cancer Therapy in Recent Years","volume":"28","author":"Tang","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 Alters T-Cell Metabolic Reprogramming by Inhibiting Glycolysis and Promoting Lipolysis and Fatty Acid Oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nm.2999","article-title":"Chemotherapy-Triggered Cathepsin B Release in Myeloid-Derived Suppressor Cells Activates the Nlrp3 Inflammasome and Promotes Tumor Growth","volume":"19","author":"Bruchard","year":"2013","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"5999","DOI":"10.2147\/OTT.S109342","article-title":"Infliximab Enhances the Therapeutic Effects of 5-Fluorouracil Resulting in Tumor Regression in Colon Cancer","volume":"9","author":"Liu","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1812266115","article-title":"Blocking IL-1beta Reverses the Immunosuppression in Mouse Breast Cancer and Synergizes With Anti-PD-1 for Tumor Abrogation","volume":"116","author":"Kaplanov","year":"2019","journal-title":"Proc Natl Acad Sci U\u00a0S A"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF Blockade Uncouples Efficacy and Toxicity in Dual CTLA-4 and PD-1 Immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.it.2021.02.006","article-title":"Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines","volume":"42","author":"Kang","year":"2021","journal-title":"Trends Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.872295\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T14:06:22Z","timestamp":1652277982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.872295\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2022.872295"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.872295","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]},"article-number":"872295"}}